These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34128866)

  • 1. Association of human T-cell leukemia virus type 1 with prevalent rheumatoid arthritis among atomic bomb survivors: A cross-sectional study.
    Hida A; Imaizumi M; French B; Ohishi W; Haruta D; Eguchi K; Nakamura H; Kawakami A
    Medicine (Baltimore); 2021 Jun; 100(24):e26297. PubMed ID: 34128866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors.
    Arisawa K; Soda M; Akahoshi M; Matsuo T; Nakashima E; Tomonaga M; Saito H
    Jpn J Cancer Res; 1998 Aug; 89(8):797-805. PubMed ID: 9765614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study.
    Umekita K; Hashiba Y; Iwao K; Iwao C; Kimura M; Kariya Y; Kubo K; Miyauchi S; Kudou R; Rikitake Y; Takajo K; Kawaguchi T; Matsuda M; Takajo I; Inoue E; Hidaka T; Okayama A
    PLoS One; 2020; 15(5):e0233159. PubMed ID: 32459801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human T-cell lymphotropic virus type-1 infection and risk of cancer: 15.4 year longitudinal study among atomic bomb survivors in Nagasaki, Japan.
    Arisawa K; Soda M; Akahoshi M; Fujiwara S; Uemura H; Hiyoshi M; Takeda H; Kashino W; Suyama A
    Cancer Sci; 2006 Jun; 97(6):535-9. PubMed ID: 16734733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
    Suzuki T; Fukui S; Umekita K; Miyamoto J; Umeda M; Nishino A; Okada A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Fujikawa K; Aramaki T; Mizokami A; Matsuoka N; Ueki Y; Eguchi K; Sato S; Hidaka T; Origuchi T; Okayama A; Kawakami A; Nakamura H
    Arthritis Rheumatol; 2018 Jul; 70(7):1014-1021. PubMed ID: 29471588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.
    Umekita K; Hidaka T; Miyauchi S; Ueno S; Kubo K; Takajo I; Hashiba Y; Kai Y; Nagatomo Y; Okayama A
    Arthritis Care Res (Hoboken); 2014 May; 66(5):788-92. PubMed ID: 24127184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.
    Birmann BM; Breen EC; Stuver S; Cranston B; Martínez-Maza O; Falk KI; Okayama A; Hanchard B; Mueller N; Hisada M
    Int J Cancer; 2009 Feb; 124(3):614-21. PubMed ID: 18989900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Human T-lymphotropic virus type-I antibodies in atomic-bomb survivors.
    Matsuo T; Nakashima E; Carter RL; Neriishi K; Mabuchi K; Akiyama M; Shimaoka K; Kinoshita K; Tomonaga M; Ichimaru M
    J Radiat Res; 1995 Mar; 36(1):8-16. PubMed ID: 7616489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of arthropathy in HTLV-I carriers on a Japanese island.
    Motokawa S; Hasunuma T; Tajima K; Krieg AM; Ito S; Iwasaki K; Nishioka K
    Ann Rheum Dis; 1996 Mar; 55(3):193-5. PubMed ID: 8712884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of evidence for human T cell lymphotrophic virus type I or II infection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Bailer RT; Lazo A; Harisdangkul V; Ehrlich GD; Gray LS; Whisler RL; Blakeslee JR
    J Rheumatol; 1994 Dec; 21(12):2217-24. PubMed ID: 7535355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High seroprevalence of anti-HTLV-I antibody in rheumatoid arthritis.
    Eguchi K; Origuchi T; Takashima H; Iwata K; Katamine S; Nagataki S
    Arthritis Rheum; 1996 Mar; 39(3):463-6. PubMed ID: 8607895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study.
    Umekita K; Hashiba Y; Kariya Y; Kubo K; Miyauchi S; Aizawa A; Umeki K; Nomura H; Kawaguchi T; Matsuda M; Takajo I; Hidaka T; Okayama A
    Mod Rheumatol; 2019 Sep; 29(5):795-801. PubMed ID: 30246572
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of Line Immunoassay to Detect HTLV-1 Infection in an Endemic Area, Southwestern Japan; Comparison with Polymerase Chain Reaction and Western Blot.
    Umeki K; Umekita K; Hashikura Y; Yamamoto I; Kubo K; Nagatomo Y; Okayama A
    Clin Lab; 2017 Feb; 63(2):227-233. PubMed ID: 28182361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies and immunoglobulins in atomic bomb survivors with human T-lymphotropic virus type I.
    Ohishi K; Shibata Y; Nakamura T; Tsujihata M; Akahoshi M; Matsuo T; Tomonaga M; Nagataki S; Shimaoka K
    Intern Med; 1996 Aug; 35(8):624-8. PubMed ID: 8894736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.
    Chang YB; Kaidarova Z; Hindes D; Bravo M; Kiely N; Kamel H; Dubay D; Hoose B; Murphy EL
    J Infect Dis; 2014 Feb; 209(4):523-31. PubMed ID: 24068702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of human T-cell lymphotropic virus and the socio-demographic and risk factors associated with the infection among post-natal clinics women in Zaria, Nigeria.
    Hananiya HS; Ella EE; Aminu M; Anyanwu NCJ
    J Immunoassay Immunochem; 2019; 40(5):485-494. PubMed ID: 31339431
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of human T-lymphotropic virus type 1 carriers among pregnant women in Hokkaido, Japan.
    Yamada T; Togashi T; Tsutsumi H; Imamura M; Okubo H; Okabe M; Takamuro N; Tashiro K; Yano K; Yamamoto N; Hirakawa Y; Minakami H
    Microbiol Immunol; 2014 Aug; 58(8):427-31. PubMed ID: 24909551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Period prevalence of uveitis in human T-lymphotropic virus 1 carriers versus noncarriers in a highly endemic area: The Nagasaki Islands Study.
    Miyata J; Yamanashi H; Dake Y; Nobusue K; Doi Y; Honda Y; Nonaka F; Arima K; Tamai M; Sasaki D; Shimizu Y; Hasegawa H; Kitaoka T; Yanagihara K; Aoyagi K; Kawakami A; Maeda T
    J Med Virol; 2024 May; 96(5):e29653. PubMed ID: 38712746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I.
    Hisada M; Okayama A; Shioiri S; Spiegelman DL; Stuver SO; Mueller NE
    Blood; 1998 Nov; 92(10):3557-61. PubMed ID: 9808547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
    Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
    Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.